Invokana bags FDA approval
The treatment has been approved to reduce the risk of hospitalisation for heart failure in certain patients with type II diabetes.
Read More
Tag: Invokana
Invokana hits endpoints in cardiovascular trial
A sub-group analysis found that the Janssen drug provided consistent CV and renal protection.
Read More
Data show J&J’s Invokana may slow or prevent CKD in diabetes patients
The data provides the first significant update in nearly 20 years regarding slowing the progression of CKD in patients with type II diabetes.
Read More
J&J submits sNDA for Invokana after premature end to clinical trial
If approved, the drug will be the only therapy in nearly 20 years to reduce the risk of end-stage kidney disease.
Read More
Mundipharma bags rights to sell Janssen’s Invokana, Vokanamet
Janssen Pharmaceutica has entered into an exclusive agreement with Mundipharma under which the latter will distribute its diabetes drugs Invokana and Vokanamet in countries in the European Economic Area (EEA) and Switzerland.
Read More
NICE backs three medicines for type 2 diabetes
Cost regulators for the NHS in England and Wales are backing the use of three monotherapies to treat patients with diabetes type 2: Janssen’s Invokana, AstraZeneca’s Forxiga and Boehringer Ingelheim/Lilly’s Jardiance.
Read More
- CERo reports encouraging early data from phase 1 trial of CER‑1236
- ENA Respiratory begins dosing in phase 2 study of INNA‑051 nasal spray
- Argo Biopharma doses first patient in phase 2b trial of BW‑20829
- Akari files new patent and advances second ADC targeting CEACAM5
- BioMed X launches kidney disease project in partnership with the government of Barbados
